Alliance for Pandemic Preparedness

March 10, 2021

The Plasmablast Response to SARS-CoV-2 MRNA Vaccination Is Dominated by Non-Neutralizing Antibodies That Target Both the NTD and the RBD

Category:

Topic:

Keywords (Tags): , ,

  • [Pre-print, not peer-reviewed] A study of vaccine-induced polyclonal antibodies and monoclonal antibodies (mAbs) from subjects who received SARS-CoV-2 mRNA vaccines found that polyclonal antibody responses were robust and comparable to or exceeded those observed after natural infection. However, most vaccine-induced mAbs did not demonstrate neutralizing activity. Neutralizing activity of N-terminal domain (NTD) mAbs, but not receptor binding domain (RBD) mAbs, against a virus carrying the E484K substitution and extensive changes in the NTD was abolished, which the authors indicate suggests that some vaccine-induced RBD-binding antibodies may protect against viral variants carrying E484K.

Amanat et al. (Mar 9, 2021). The Plasmablast Response to SARS-CoV-2 MRNA Vaccination Is Dominated by Non-Neutralizing Antibodies That Target Both the NTD and the RBD. Pre-print downloaded Mar 10 from https://doi.org/10.1101/2021.03.07.21253098